



# MEDIVIR Q3 CALL 10 NOVEMBER 2020

**MEDIVIR**  
SCIENCE WORKING WONDERS

# Today's presenters

President and CEO



Yilmaz Mahshid

Chief Financial Officer



Magnus Christensen

# Important notice

You must read the following before continuing. The following applies to this document and the information provided in this presentation by Medivir AB (publ) (the "Company") or any person on behalf of the Company and any other material distributed or statements made in connection with such presentation (the "Information"), and you are therefore advised to carefully read the statements below before reading, accessing or making any other use of the Information. In accessing the Information, you agree to be bound by the following terms and conditions.

The Information does not constitute or form part of, and should not be construed as, an offer of invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or a successor entity or any existing or future subsidiary or affiliate of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any of such subsidiaries or affiliates nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a "prospectus" within the meaning of the U.S. Securities Act of 1933, as amended.

The Information may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not for publication, release or distribution in the United States, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful.

All of the Information herein has been prepared by the Company solely for use in this presentation. The Information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained herein. The Information contained in this presentation should be considered in the context of the circumstances prevailing at that time and will not be updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company's operations, financial position and earnings. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to, implementation of the Company's strategy and its ability to further grow, risks associated with the development and/or approval of the Company's products candidates, ongoing clinical trials and expected trial results, the ability to commercialize existing and any future products, technology changes and new products in the Company's potential market and industry, the ability to develop new products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. While the Company always intends to express its best judgment when making statements about what it believes will occur in the future, and although the Company bases these statements on assumptions that it believes to be reasonable when made, these forward-looking statements are not a guarantee of its performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically decline, any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.

# Executive summary

## Proprietary clinical asset

- MIV-818 – A liver directed nucleotide prodrug
- In phase Ib clinical development
- Opportunities for breakthrough oncology indications

## The company

- Building on an experienced leadership team and effective organization
- Focus on clinical development in unmet oncology indications

## Multiple programs for partnering/out-licensing

- Remetinostat, Birinapant and MIV-711

Founded: 1988

Listed: Nasdaq OMX

Location: Stockholm

Cash position: SEK 83M<sup>1)</sup>

Market Cap: SEK 340M<sup>2)</sup>

FTE: 9

1) Q3 report  
2) 2020-11-09

# Focused clinical program

Nucleotide prodrug	Indication	Research	Preclinical	Phase I	Exclusivity	
MIV-818	Liver cancer					IP : 2035

# Multiple programs for partnering/out-licensing

Compound	Mechanism	Indication	Phase I	Phase II	Phase III	Exclusivity
Remetinostat	Topical HDAC	MF-CTCL <sup>1)</sup> BCC				IP : 2034
Birinapant	SMAC mimetic	HNSCC <sup>2)</sup>				IP : 2034
MIV-711	Cathepsin K inhibitor	OA <sup>3)</sup>				IP : 2034

1) Indications: basal cell carcinoma, squamous cell carcinoma, mycosis fungoides cutaneous T-cell lymphoma (phase III ready)

2) Head and neck squamous cell carcinoma

3) Osteoarthritis




# MIV-818

## Mode of action and preclinical data

# MIV-818: A liver-directed nucleotide

- MIV-818 is an oral prodrug
- Once absorbed from the GI-tract, MIV-818 is transported to the liver
- The prodrug is taken up by liver cancer cells and converted into troxacitabine triphosphate (TRX-TP)
- TRX-TP is incorporated into DNA and causes double-strand DNA breaks and cell death

MIV-818 (prodrug)



# Preclinical evidence for MIV-818 liver targeting


Compound	Route	Dose (μmol/kg)	Liver TRX-TP/Plasma TRX (AUC ratio)
Troxacitabine (TRX)	<i>iv</i>	80	<0.016
MIV-818	<i>oral</i>	80	1.9

- MIV-818 exhibited substantial liver targeting by preferential formation of the active TRX-TP metabolite in liver of rats
- MIV-818 shows a 100-fold higher liver targeting than troxacitabine




# MIV-818 shows efficacy in preclinical HCC models

Inhibition of tumor growth in mouse HCC xenograft models in vivo



Inhibition of patient-derived HCC cell lines in vitro




# MIV-818

## Clinical development


# MIV-818: Selective effect signal in liver cancer in phase Ia

- Clear signs of cell death, measured as DNA damage, observed in liver biopsies from tumor tissue in MIV-818 treated patients
- The tumor selective effect is an early proof-of-concept of the intended liver-directed effect in patients



Evidence of DNA damage (brown coloring) in tumor but not in normal liver tissue

# MIV-818: Clinical development plan in advanced liver cancer







SoC = Standard of Care



# Other assets

# Multiple programs for partnering/out-licensing

Compound	Mechanism	Indication	Phase I	Phase II	Phase III	Exclusivity
Remetinostat	Topical HDAC	MF-CTCL <sup>1)</sup> BCC				IP : 2034
Birinapant	SMAC mimetic	HNSCC <sup>2)</sup>				IP : 2034
MIV-711	Cathepsin K inhibitor	OA <sup>3)</sup>				IP : 2034

1) Indications: basal cell carcinoma, squamous cell carcinoma, mycosis fungoides cutaneous T-cell lymphoma (phase III ready)

2) Head and neck squamous cell carcinoma

3) Osteoarthritis



# Financial summary

# Financial summary

## Consolidated Income Statement, summary

(SEK m)

	Q3		Q1 - Q3		Full year
	2020	2019	2020	2019	2019
Net turnover	1.1	1.7	12.5	7.3	8.7
Other operating income	15.7	-1.2	16.3	-0.3	-1.5
<b>Total income</b>	<b>16.8</b>	<b>0.4</b>	<b>28.7</b>	<b>7.1</b>	<b>7.2</b>
Other external expenses	-6.6	-17.6	-37.8	-68.7	-91.1
Personnel costs	-4.9	-4.7	-18.7	-27.0	-35.0
Depreciations and write-downs	-1.1	-1.7	-3.8	-5.4	-7.1
<b>Operating profit/loss</b>	<b>4.2</b>	<b>-23.7</b>	<b>-31.6</b>	<b>-94.0</b>	<b>-126.0</b>
Net financial items	0.5	0.7	0.1	2.7	2.6
<b>Profit/loss after financial items</b>	<b>4.6</b>	<b>-23.0</b>	<b>-31.5</b>	<b>-91.3</b>	<b>-123.3</b>
Tax	-	-0.1	-	-0.1	-0.1
<b>Net profit/loss for the period</b>	<b>4.6</b>	<b>-23.1</b>	<b>-31.5</b>	<b>-91.4</b>	<b>-123.4</b>

- Net turnover for Q3 2020 was SEK 1.1 million and for Q1-Q3 SEK 12.5 million
- Other operating income relates mainly to the effect of renegotiated lease agreement
- Profit for the Q3 2020 was SEK 5 million and loss for Q1-Q3 SEK -32 million
- Cash flow from operating activities for Q3 2020 was SEK -17.1 million and for Q1-Q3 SEK -57.1 million
- 9 FTE end of Q3 2020
- Cash position as of September 30, 2020: SEK 83 million

# Executive summary

## Proprietary clinical asset

- MIV-818 – A liver directed nucleotide-prodrug
- In phase Ib clinical development
- Data from part A expected in Q1-2021

## The company

- Building on an experienced leadership team and effective organization
- Focus on clinical development in unmet oncology indications

## Multiple programs for partnering/out-licensing

- Remetinostat, Birinapant and MIV-711

Founded: 1988

Listed: Nasdaq OMX

Location: Stockholm

Cash position: c. SEK 83M<sup>1)</sup>

Market Cap: SEK 340M<sup>2)</sup>

FTE: 9

<sup>1)</sup> Q3 REPORT

<sup>2)</sup> 2020-11-09